BPG is committed to discovery and dissemination of knowledge
Case Control Study
©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 113172
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.113172
Table 4 Univariate analysis of biomarker intensities: Comparison of biological treatment initiation by 1 year

No biologic treatment (n = 75)
Biologic treatment (n = 48)
P value
Female, n (%)33 (44.0)12 (25.0)0.052
Ethnicity, n (%)0.56
    Western European50 (66.7)34 (70.8)
    South Asian13 (17.3)5 (10.4)
    Other12 (16.0)9 (18.8)
Age (year)13.0 ± 3.0712.5 ± 2.390.353
Biomarker
    CCL2104 ± 37.1105 ± 54.10.937
    CCL51722 ± 7701798 ± 14790.742
    CCL7283 ± 138269 ± 1080.532
    IL-840.5 ± 21715.1 ± 13.40.316
    TSLP308 ± 106286 ± 1280.323
    CCL344.2 ± 11.946.2 ± 17.30.498
    CXCL1297 ± 257415 ± 3300.039
    CXCL2176 ± 204241 ± 2010.083
    CXCL94087 ± 34704102 ± 28280.979
    IL-18137 ± 123214 ± 2800.08
    IL-2264.9 ± 23343.8 ± 16.00.438
    TARC379 ± 641288 ± 1460.238


Write to the Help Desk